A closer look at Fierce Biotech's Fierce 15

Published on August 12, 2024

In this week's episode of "The Top Line," we’re diving into Fierce Biotech’s annual Fierce 15 special report. 

Fierce Biotech's Annalee Armstrong and Gabrielle Masson take you behind the scenes to explore the meticulous selection process and share interesting highlights from this year’s honorees. 

To learn more about the topics in this episode: 

Continue reading on website
Other news

Merck bets $700M on an antibody drug’s potential in immune diseases

August 12, 2024
Merck & Co. on Friday acquired an experimental drug designed to wipe out the immune system’s B cells in a deal that adds to a surge of industry interest in using so-called bispecific antibodies to treat autoimmune diseases.Per deal terms, Merck will pay Curon Biopharmaceutical, a privately held, China-based biotechnology company, $700 million upfront for rights to a treatment code-named CN201. Mer

Pfizer Canada Ranked #1 by 100 Canadian Patient Advocacy Groups

August 13, 2024
PatientView survey is an annual global study that gives patient advocacy groups an opportunity to comment on, and assess, the pharma industry’s performanceKIRKLAND, QC – Pfizer is proud to announce that it has been ranked as the most reputable pharmaceutical company in Canada by Patient Advocacy Groups (PAGs) in the 2023 PatientView survey. This recognition highlights Pfizer Canada’s commitment to